PUBLISHER: Grand View Research | PRODUCT CODE: 1433539
PUBLISHER: Grand View Research | PRODUCT CODE: 1433539
The global gRNA market size is anticipated to reach USD 1.62 billion by 2030 and it is projected to grow at a CAGR of 18.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising adoption of Next-Generation Sequencing (NGS) is significantly boosting the market. As NGS technologies become more prevalent, they empower researchers and scientists with advanced capabilities for genomic analysis and manipulation. NGS enables high-throughput sequencing of genetic material, allowing for the rapid and cost-effective examination of entire genomes. This efficiency is crucial for gRNA applications, as it facilitates the identification and validation of target genes for genetic manipulation. NGS technologies provide a precise and comprehensive understanding of genomic sequences. This precision is vital for designing gRNAs with high specificity, ensuring accurate targeting of genes during the gene editing process using CRISPR/Cas systems.
Furthermore, the increasing investments by biotechnology and pharmaceutical companies for R&D activities are expected to fuel the market in the coming years. The development of user-friendly and affordable gRNA synthesis kits and services has made CRISPR-Cas9 technology more accessible to researchers of all levels. The continuous discovery of novel applications for CRISPR-Cas9 fuels the demand for gRNA.
Additionally, the launch of new gRNA final products can drive innovation, expand the market reach of players, and accelerate the adoption of gene editing technologies, contributing to the overall growth & advancement of the market. For instance, in October 2023, Synthego, a prominent provider of genome engineering solutions, launched IND-enabling (INDe) gRNAs. This transformative offering marks a significant advancement in the CRISPR-based cell and gene therapy preclinical pipeline. By providing researchers with high-quality gRNAs meticulously designed for GLP-regulated preclinical and IND-enabling studies, this product incorporates comprehensive IND-compliant materials and documentation throughout its design and production. Thus, it will drive the market growth.